EZH1 and non-small cell lung carcinoma: Similarly, reduced sensitivity to erlotinib in non-small cell lung cancer (NSCLC) has been associated with miR-17-dependent overexpression of enhancer of zeste homolog 1 (EZH1), a member of the EZH family implicated in drug resistance across multiple malignancies [9].